RESUMEN
Tks5/Fish is a scaffolding protein with five SH3 domains and one PX domain. In Src-transformed cells, Tks5/Fish localizes to podosomes, discrete protrusions of the ventral membrane. We generated Src-transformed cells with reduced Tks5/Fish levels. They no longer formed podosomes, did not degrade gelatin, and were poorly invasive. We detected Tks5/Fish expression in podosomes in invasive cancer cells, as well as in human breast cancer and melanoma samples. Tks5/Fish expression was also required for protease-driven matrigel invasion in human cancer cells. Finally, coexpression of Tks5/Fish and Src in epithelial cells resulted in the appearance of podosomes. Thus, Tks5/Fish appears to be required for podosome formation, for degradation of the extracellular matrix, and for invasion of some cancer cells.
Asunto(s)
Proteínas Adaptadoras del Transporte Vesicular/fisiología , Neoplasias/metabolismo , Péptido Hidrolasas/química , Proteínas Adaptadoras del Transporte Vesicular/metabolismo , Animales , Neoplasias de la Mama/metabolismo , Línea Celular , Línea Celular Tumoral , Pollos , Matriz Extracelular/metabolismo , Humanos , Melanoma/metabolismo , Ratones , Microscopía Fluorescente , Células 3T3 NIH , Invasividad Neoplásica , Estructura Terciaria de Proteína , ARN Interferente Pequeño/metabolismo , Dominios Homologos src , Familia-src Quinasas/metabolismoRESUMEN
Understanding the basic principles that govern RNA binding by aminoglycosides is important for the design of new generations of antibiotics that do not suffer from the known mechanisms of drug resistance. With this goal in mind, we examined the binding of kanamycin A and four derivatives (the products of enzymic turnovers of kanamycin A by aminoglycoside-modifying enzymes) to a 27 nucleotide RNA representing the bacterial ribosomal A site. Modification of kanamycin A functional groups that have been directly implicated in the maintenance of specific interactions with RNA led to a decrease in affinity for the target RNA. Overall, the products of reactions catalyzed by aminoglycoside resistance enzymes exhibit diminished binding to the A site of bacterial 16S rRNA, which correlates well with a loss of antibacterial ability in resistant organisms that harbor these enzymes.
Asunto(s)
Antibacterianos/metabolismo , Oligorribonucleótidos/metabolismo , ARN Ribosómico 16S/metabolismo , Antibacterianos/química , Antibacterianos/farmacología , Sitios de Unión , Resistencia a Medicamentos , Enzimas/metabolismo , Escherichia coli/efectos de los fármacos , Kanamicina/metabolismo , Kanamicina/farmacología , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Neomicina/metabolismo , Neomicina/farmacología , ARN Bacteriano/metabolismo , Relación Estructura-ActividadRESUMEN
The structure of neamine bound to the A site of the bacterial ribosomal RNA was used in the design of novel aminoglycosides. The design took into account stereo and electronic contributions to interactions between RNA and aminoglycosides, as well as a random search of 273 000 compounds from the Cambridge structural database and the National Cancer Institute 3-D database that would fit in the ribosomal aminoglycoside-binding pocket. A total of seven compounds were designed and subsequently synthesized, with the expectation that they would bind to the A-site RNA. Indeed, all synthetic compounds were found to bind to the target RNA comparably to the parent antibiotic neamine, with dissociation constants in the lower micromolar range. The synthetic compounds were evaluated for antibacterial activity against a set of important pathogenic bacteria. These designer antibiotics showed considerably enhanced antibacterial activities against these pathogens, including organisms that hyperexpressed resistance enzymes to aminoglycosides. Furthermore, analyses of four of the synthetic compounds with two important purified resistance enzymes for aminoglycosides indicated that the compounds were very poor substrates; hence the activity of these synthetic antibiotics does not appear to be compromised by the existing resistance mechanisms, as supported by both in vivo and in vitro experiments. The design principles disclosed herein hold the promise of the generation of a large series of designer antibiotics uncompromised by the existing mechanisms of resistance.